Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 212

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA)

Open access
Hamanishi, Junzo, Takeshima, Nobuhiro, Katsumata, Noriyuki, Ushijima, Kimio, Kimura, Tadashi, Takeuchi, Satoshi, Matsumoto, Koji, Ito, Kimihiko, Mandai, Masaki, Nakai, Hidekatsu, Sakuragi, Noriaki, Watari, Hidemichi, Takahashi, Nobutaka, Kato, Hidenori, Hasegawa, Kosei, Yonemori, Kan, Mizuno, Mika, Takehara, Kazuhiro, Niikura, Hitoshi, Sawasaki, Takashi, Nakao, Sari, Saito, Toshiaki, Enomoto, Takayuki, Nagase, Satoru, Suzuki, Nao, Matsumoto, Takashi, Kondo, Eiji, Sonoda, Kenzo, Aihara, Satomi, Aoki, Yoichi, Okamoto, Aikou, Takano, Hirokuni, Kobayashi, Hiroshi, Kato, Hisamori, Terai, Yoshito, Takazawa, Akira, Takahashi, Yusuke, Namba, Yoshinobu, Aoki, Daisuke, Fujiwara, Keiichi, Sugiyama, Toru, Konishi, Ikuo · 2021 · Journal of Clinical Oncology

Abstract

PURPOSE: This phase III, multicenter, randomized, open-label study investigated the efficacy and safety of nivolumab versus chemotherapy (gemcitabine [GEM] or pegylated liposomal doxorubicin [PLD]) in patients with platinum-resistant ovarian cancer. MATERIALS AND METHODS: Eligible patients had platinum-resistant epithelial ovarian cancer, received ≤ 1 regimen after diagnosis of resistance, and had an Eastern Cooperative Oncology Group performance score of ≤ 1. Patients were randomly assigned 1:1 to nivolumab (240 mg once every 2 weeks [as one cycle]) or chemotherapy (GEM 1000 mg/m 2 for 30 minutes [once on days 1, 8, and 15] followed by a week's rest [as one cycle], or PLD 50 mg/m 2 once every 4 weeks [as one cycle]). The primary outcome was overall survival (OS). Secondary outcomes included progression-free survival (PFS), overall response rate, duration of response, and safety. RESULTS: Patients (n = 316) were randomly assigned to nivolumab (n = 157) or GEM or PLD (n = 159) between October 2015 and December 2017. Median OS was 10.1 (95% CI, 8.3 to 14.1) and 12.1 (95% CI, 9.3 to 15.3) months with nivolumab and GEM or PLD, respectively (hazard ratio, 1.0; 95% CI, 0.8 to 1.3; P = .808). Median PFS was 2.0 (95% CI, 1.9 to 2.2) and 3.8 (95% CI, 3.6 to 4.2) months with nivolumab and GEM or PLD, respectively (hazard ratio, 1.5; 95% CI, 1.2 to 1.9; P = .002). There was no statistical difference in overall response rate between groups (7.6% v 13.2%; odds ratio, 0.6; 95% CI, 0.2 to 1.3; P = .191). Median duration of response was numerically longer with nivolumab than GEM or PLD (18.7 v 7.4 months). Fewer treatment-related adverse events were observed with nivolumab versus GEM or PLD (61.5% v 98.1%), with no additional or new safety risks. CONCLUSION: Although well-tolerated, nivolumab did not improve OS and showed worse PFS compared with GEM or PLD in patients with platinum-resistant ovarian cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.21.00334

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 212

Metadata

Authors
Hamanishi, J., Takeshima, N., Katsumata, N., Ushijima, K., Kimura, T., Takeuchi, S., Matsumoto, K., Ito, K., Mandai, M., Nakai, H., Sakuragi, N., Watari, H., Takahashi, N., Kato, H., Hasegawa, K., Yonemori, K., Mizuno, M., Takehara, K., Niikura, H., Sawasaki, T., Nakao, S., Saito, T., Enomoto, T., Nagase, S., Suzuki, N., Matsumoto, T., Kondo, E., Sonoda, K., Aihara, S., Aoki, Y., Okamoto, A., Takano, H., Kobayashi, H., Kato, H., Terai, Y., Takazawa, A., Takahashi, Y., Namba, Y., Aoki, D., Fujiwara, K., Sugiyama, T., & Konishi, I.
Venue
Journal of Clinical Oncology
Published
2021-11-20
Volume
39
Issue
33
Pages
3671-3681
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W3198783816
Cited by
212
References
6
FWCI
22.19
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA). https://app.cochat.ai/papers/10.1200/jco.21.00334
The paper
Hamanishi, J., Takeshima, N., Katsumata, N., Ushijima, K., Kimura, T., Takeuchi, S., Matsumoto, K., Ito, K., Mandai, M., Nakai, H., Sakuragi, N., Watari, H., Takahashi, N., Kato, H., Hasegawa, K., Yonemori, K., Mizuno, M., Takehara, K., Niikura, H., . . . Konishi, I. (2021). Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA). Journal of Clinical Oncology. https://doi.org/10.1200/jco.21.00334

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.